Cargando…

Future Risks in Patients With Severe Asthma

A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Woo-Jung, Lee, Ji-Hyang, Kang, Yewon, Joung, Woo Joung, Chung, Kian Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761069/
https://www.ncbi.nlm.nih.gov/pubmed/31552713
http://dx.doi.org/10.4168/aair.2019.11.6.763
_version_ 1783453944795627520
author Song, Woo-Jung
Lee, Ji-Hyang
Kang, Yewon
Joung, Woo Joung
Chung, Kian Fan
author_facet Song, Woo-Jung
Lee, Ji-Hyang
Kang, Yewon
Joung, Woo Joung
Chung, Kian Fan
author_sort Song, Woo-Jung
collection PubMed
description A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with ‘controlled’ severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control.
format Online
Article
Text
id pubmed-6761069
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
record_format MEDLINE/PubMed
spelling pubmed-67610692019-11-01 Future Risks in Patients With Severe Asthma Song, Woo-Jung Lee, Ji-Hyang Kang, Yewon Joung, Woo Joung Chung, Kian Fan Allergy Asthma Immunol Res Review A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with ‘controlled’ severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019-07-08 /pmc/articles/PMC6761069/ /pubmed/31552713 http://dx.doi.org/10.4168/aair.2019.11.6.763 Text en Copyright © 2019 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Song, Woo-Jung
Lee, Ji-Hyang
Kang, Yewon
Joung, Woo Joung
Chung, Kian Fan
Future Risks in Patients With Severe Asthma
title Future Risks in Patients With Severe Asthma
title_full Future Risks in Patients With Severe Asthma
title_fullStr Future Risks in Patients With Severe Asthma
title_full_unstemmed Future Risks in Patients With Severe Asthma
title_short Future Risks in Patients With Severe Asthma
title_sort future risks in patients with severe asthma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761069/
https://www.ncbi.nlm.nih.gov/pubmed/31552713
http://dx.doi.org/10.4168/aair.2019.11.6.763
work_keys_str_mv AT songwoojung futurerisksinpatientswithsevereasthma
AT leejihyang futurerisksinpatientswithsevereasthma
AT kangyewon futurerisksinpatientswithsevereasthma
AT joungwoojoung futurerisksinpatientswithsevereasthma
AT chungkianfan futurerisksinpatientswithsevereasthma